Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

10.16 -0.28 (-2.68%)

Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up ↗

August 12, 2026

Candel Therapeutics (NASDAQ:CADL) is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief...

Via MarketBeat

Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data ↗

May 20, 2026

Candel Therapeutics (NASDAQ:CADL) Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer...

Via MarketBeat

Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today ↗

February 19, 2026

Candel is pushing ahead with an equity raise and also lined up $100 million in royalty funding from RTW Investments, contingent on FDA approval of CAN-2409.

Via Stocktwits

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗

December 05, 2025

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.

Via Stocktwits

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer ↗

October 14, 2025

Via Stocktwits

How Is The Market Feeling About Candel Therapeutics? ↗

January 08, 2025

Via Benzinga

EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards ↗

October 23, 2025

Trinity Capital Inc. announced a financing agreement with Bobbie, an organic infant nutrition company, to boost production capacity and ensure wider distribution of its products.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 03, 2025

Via Benzinga

Candel Reports 88 Percent Q2 Loss Drop ↗

August 14, 2025

Via The Motley Fool

ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

July 16, 2025

Via Benzinga

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy ↗

May 28, 2025

Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application.

Via Stocktwits

Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On? ↗

May 28, 2025

Candel Therapeutics stock rose after its prostate cancer therapy, CAN-2409, received FDA RMAT designation. This expedites development and review, following positive Phase 3 trial results.

Via Benzinga

Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish ↗

May 13, 2025

The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.

Via Stocktwits

Top movers in Wednesday's after hours session ↗

April 23, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 23, 2025

Via Benzinga

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients ↗

March 27, 2025

Candel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in non-squamous cases and a strong safety profile.

Via Benzinga

Candel Therapeutics Shares Are Down Today: What's Going On? ↗

March 27, 2025

Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.

Via Benzinga

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism ↗

March 27, 2025

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.

Via Stocktwits

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week ↗

February 23, 2025

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Via Stocktwits

This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

February 20, 2025

Via Benzinga

Major Indexes Falter; Dow Drops Over 550 Points ↗

February 20, 2025

The Dow Jones Industrial Average is down 556 points midday, heading for its worst daily percentage loss since mid January, while the S&P 500 Index and Nasdaq Composite sit firmly in the red as well.

Via Talk Markets

Topics Stocks Stocks / Equities

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

February 20, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice ↗

February 20, 2025

CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.

Via Stocktwits

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

February 19, 2025

Via Benzinga

Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call ↗

February 07, 2025

The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.

Via Stocktwits

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

February 07, 2025

Via Benzinga

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

December 20, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 13, 2024

Via Benzinga

What's Going On With Candel Therapeutics Shares Friday? ↗

December 13, 2024

Candel shares are moving lower on Friday after the company priced its $80 million underwritten public offering of shares and pre-funded warrants.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.